Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study
Abstract Background Fibroblast growth factor-23 (FGF23) and α-klotho are associated with anemia in patients with chronic kidney disease. In this post hoc analysis of the ASTRIO study (UMIN000019176), we investigated the relationship between FGF23 and α-klotho during treatment with an iron-based phos...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-021-02575-9 |
| _version_ | 1818916316699951104 |
|---|---|
| author | Kyoko Ito Keitaro Yokoyama Masaaki Nakayama Masafumi Fukagawa Hideki Hirakata |
| author_facet | Kyoko Ito Keitaro Yokoyama Masaaki Nakayama Masafumi Fukagawa Hideki Hirakata |
| author_sort | Kyoko Ito |
| collection | DOAJ |
| description | Abstract Background Fibroblast growth factor-23 (FGF23) and α-klotho are associated with anemia in patients with chronic kidney disease. In this post hoc analysis of the ASTRIO study (UMIN000019176), we investigated the relationship between FGF23 and α-klotho during treatment with an iron-based phosphate binder, ferric citrate hydrate (FC), compared with non-iron-based phosphate binders in hemodialysis (HD) patients. We examined the effect of iron absorption by FC on the relationship between FGF23 and α-klotho. There have been few clinical studies evaluating these biomarkers simultaneously in HD patients. Methods The ASTRIO study was a 24-week, randomized, open-label, multicenter trial. HD patients taking non-iron-based phosphate binder(s) were randomized at a 1:1 ratio to continue other binder(s) (control group) or switch to FC (FC group). Serum phosphate (P) and hemoglobin (Hb) were maintained within 3.5–6.0 mg/dL and 10–12 g/dL, respectively. Plasma levels of intact FGF23 (i-FGF23), C-terminal FGF23 (c-FGF23), and α-klotho were measured, as were iron-related parameters. Association analyses of FGF23 and α-klotho were conducted. Results Patients were randomized to FC (n = 48) and control (n = 45) groups. Serum ferritin significantly increased from baseline to end-of-treatment (EOT) in the FC group, compared with the control group (adjusted mean difference [95% confidence interval]: 79.5 [44.7, 114.4] ng/mL; p < 0.001). The mean change from baseline to EOT in c-FGF23 was significantly different between the FC and control groups (mean ± standard deviation (SD): − 0.2 ± 0.8 loge pg/mL vs. 0.2 ± 0.8 loge pg/mL, respectively; p = 0.04). The mean change from baseline to EOT in i-FGF23 and α-klotho were not significantly different between the FC and control groups (mean ± SD: − 0.1 ± 0.8 loge pg/mL vs. 0.1 ± 0.9 loge pg/mL; p = 0.33, and 2.0 ± 91.5 pg/mL vs. − 8.9 ± 145.3; p = 0.58, respectively). However, both forms of FGF23 and α-klotho were not significantly associated with each other in both groups. Conclusions Iron absorbed via FC administration in HD patients did not influence the correlation relationship between plasma levels of FGF23 and α-klotho under the condition of serum P and Hb were maintained. Trial registration ASTRIO study ( UMIN000019176 , registered at UMIN Clinical Trials Registry on October 1, 2015). |
| first_indexed | 2024-12-20T00:16:14Z |
| format | Article |
| id | doaj.art-75f8f795c9ba4dac989e29a7b7c58b1c |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-20T00:16:14Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-75f8f795c9ba4dac989e29a7b7c58b1c2022-12-21T20:00:20ZengBMCBMC Nephrology1471-23692021-11-0122111210.1186/s12882-021-02575-9Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO studyKyoko Ito0Keitaro Yokoyama1Masaaki Nakayama2Masafumi Fukagawa3Hideki Hirakata4Medical Affairs Department, Torii Pharmaceutical Co. Ltd.Health Care Center, Harumi Toriton Clinic, The Jikei University HospitalSt. Luke’s International University, St. Luke’s International HospitalDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of MedicineFukuoka Renal ClinicAbstract Background Fibroblast growth factor-23 (FGF23) and α-klotho are associated with anemia in patients with chronic kidney disease. In this post hoc analysis of the ASTRIO study (UMIN000019176), we investigated the relationship between FGF23 and α-klotho during treatment with an iron-based phosphate binder, ferric citrate hydrate (FC), compared with non-iron-based phosphate binders in hemodialysis (HD) patients. We examined the effect of iron absorption by FC on the relationship between FGF23 and α-klotho. There have been few clinical studies evaluating these biomarkers simultaneously in HD patients. Methods The ASTRIO study was a 24-week, randomized, open-label, multicenter trial. HD patients taking non-iron-based phosphate binder(s) were randomized at a 1:1 ratio to continue other binder(s) (control group) or switch to FC (FC group). Serum phosphate (P) and hemoglobin (Hb) were maintained within 3.5–6.0 mg/dL and 10–12 g/dL, respectively. Plasma levels of intact FGF23 (i-FGF23), C-terminal FGF23 (c-FGF23), and α-klotho were measured, as were iron-related parameters. Association analyses of FGF23 and α-klotho were conducted. Results Patients were randomized to FC (n = 48) and control (n = 45) groups. Serum ferritin significantly increased from baseline to end-of-treatment (EOT) in the FC group, compared with the control group (adjusted mean difference [95% confidence interval]: 79.5 [44.7, 114.4] ng/mL; p < 0.001). The mean change from baseline to EOT in c-FGF23 was significantly different between the FC and control groups (mean ± standard deviation (SD): − 0.2 ± 0.8 loge pg/mL vs. 0.2 ± 0.8 loge pg/mL, respectively; p = 0.04). The mean change from baseline to EOT in i-FGF23 and α-klotho were not significantly different between the FC and control groups (mean ± SD: − 0.1 ± 0.8 loge pg/mL vs. 0.1 ± 0.9 loge pg/mL; p = 0.33, and 2.0 ± 91.5 pg/mL vs. − 8.9 ± 145.3; p = 0.58, respectively). However, both forms of FGF23 and α-klotho were not significantly associated with each other in both groups. Conclusions Iron absorbed via FC administration in HD patients did not influence the correlation relationship between plasma levels of FGF23 and α-klotho under the condition of serum P and Hb were maintained. Trial registration ASTRIO study ( UMIN000019176 , registered at UMIN Clinical Trials Registry on October 1, 2015).https://doi.org/10.1186/s12882-021-02575-9ASTRIO studyFerric citrate hydrateFGF23α-KlothoHemodialysisiron-based phosphate binder |
| spellingShingle | Kyoko Ito Keitaro Yokoyama Masaaki Nakayama Masafumi Fukagawa Hideki Hirakata Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study BMC Nephrology ASTRIO study Ferric citrate hydrate FGF23 α-Klotho Hemodialysis iron-based phosphate binder |
| title | Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study |
| title_full | Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study |
| title_fullStr | Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study |
| title_full_unstemmed | Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study |
| title_short | Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study |
| title_sort | association of fibroblast growth factor 23 and α klotho in hemodialysis patients during administration of ferric citrate hydrate post hoc analysis of astrio study |
| topic | ASTRIO study Ferric citrate hydrate FGF23 α-Klotho Hemodialysis iron-based phosphate binder |
| url | https://doi.org/10.1186/s12882-021-02575-9 |
| work_keys_str_mv | AT kyokoito associationoffibroblastgrowthfactor23andaklothoinhemodialysispatientsduringadministrationofferriccitratehydrateposthocanalysisofastriostudy AT keitaroyokoyama associationoffibroblastgrowthfactor23andaklothoinhemodialysispatientsduringadministrationofferriccitratehydrateposthocanalysisofastriostudy AT masaakinakayama associationoffibroblastgrowthfactor23andaklothoinhemodialysispatientsduringadministrationofferriccitratehydrateposthocanalysisofastriostudy AT masafumifukagawa associationoffibroblastgrowthfactor23andaklothoinhemodialysispatientsduringadministrationofferriccitratehydrateposthocanalysisofastriostudy AT hidekihirakata associationoffibroblastgrowthfactor23andaklothoinhemodialysispatientsduringadministrationofferriccitratehydrateposthocanalysisofastriostudy |